IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
| 11.18 | |
| 12.07 | |
| - | |
| 12.25 | |
| 10.94 | |
| 3.81-17.7 | |
| 714 M | |
| 33 637 K | |
| 2 105 K | |
| -0.83 | |
| 0.189 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
IGM Biosciences IGMS, a clinical-stage company, is developing a pipeline of Immunoglobin M (IgM) antibody-based candidates to treat patients with cancer and autoimmune and inflammatory diseases. The ...
IGM Biosciences, Inc. MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM anti...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
